腫瘤

CheckMate 9LA 近兩年更新:晚期非小細胞肺癌(NSCLC)患者的一線 nivolumab (NIVO)+ ipilimumab(IPI)聯合 2 個周期化療(chemo)VS 單藥化療(4 個周期)

作者:會飛的大胖紙 來源:醫學論壇網 日期:2021-06-30
導讀

背景:在 3 期隨機 CheckMate 9LA 試驗(NCT03215706)中,一線 NIVO + IPI 聯合2 周期化療與單藥化療 4 周期相比,顯著改延長了總生存期 (OS), 無進展生存期 (PFS)和客觀應答率 (ORR)。無論 PD-L1 表達水平和組織學分型如何,我們都觀察到臨床療效。我們將在此彙報至少 2 年的跟蹤隨訪數據。 Background: In the rando

關鍵字: 腫瘤

背景:在 3 期隨機 CheckMate 9LA 試驗(NCT03215706)中,一線 NIVO + IPI 聯合2 周期化療與單藥化療 4 周期相比,顯著改延長了總生存期 (OS), 無進展生存期 (PFS)和客觀應答率 (ORR)。無論 PD-L1 表達水平和組織學分型如何,我們都觀察到臨床療效。我們將在此彙報至少 2 年的跟蹤隨訪數據。

Background: In the randomized phase 3 CheckMate 9LA trial (NCT03215706), first-line NIVO + IPI combined with 2 cycles of chemo significantly improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) vs chemo alone (4 cycles). Clinical benefit was observed regardless of programmed death ligand 1 (PD-L1) expression level and histology. Here we report data with 2 years’ minimum follow-up from this study.

方法:我們將 IV 期或複發 NSCLC、ECOG 評分≤1 分 和已知無明確 EGFR/ALK 突變的成人患者(pts)按 PD-L1(< 1% 與 ≥1%),性別,和組織學表型 (鱗癌 VS 非鱗癌)分層,並被 1:1 隨機分組到 NIVO 360 mg Q3W + IPI 1 mg / kg Q6W + 化療 (2 周期; n = 361) 或單藥化療 (4 周期; n = 358)。在化療組中非鱗 NSCLC 的 pts 可以接受培美曲塞維持。主要終點是 OS。次要終點包括通過獨立中心盲審的 PFS 和 ORR,以及 PD-L1 不同等級的療效。此研究的安全性是得以保證的。

Methods: Adult patients (pts) with stage IV / recurrent NSCLC, ECOG performance status ≤ 1, and no known sensitizing EGFR/ALK alterations were stratified by PD-L1 (< 1% vs ≥ 1%), sex, and histology (squamous vs non-squamous) and were randomized 1:1 to NIVO 360 mg Q3W + IPI 1 mg/kg Q6W + chemo (2 cycles; n = 361) or chemo alone (4 cycles; n = 358). Pts with non-squamous NSCLC in the chemo-alone arm could receive pemetrexed maintenance. The primary endpoint was OS. Secondary endpoints included PFS and ORR by blinded independent central review, and efficacy by different PD-L1 levels. Safety was exploratory.

結果:OS 至少隨訪 24.4 個月(數據庫於 2021 年 2 月 18 日鎖定),經 NIVO + IPI + chemo 治療的 pts 與單藥化療相比得到了 OS 獲益,中位 OS 分別為 15.8 個月與 11.0 個月(HR, 0.72 [95% CI, 0.61–0.86]);2 年 OS 率分別為 38%和 26%。經 NIVO + IPI + chemo 治療與單藥化療的中位 PFS 分別為 6.7 個月與 5.3 個月 (HR,0.67 [95% CI,0.56-0.79]);分別有 8%和 37%的有疾病進展的患者接受了後續免疫治療。NIVO+IPI+chemo ORR 38% VS 單藥化療 ORR 25%。在所有隨機分組的 pts 和大多數子分組都觀察到了類似於 NIVO+ IPI + chemo VS 單藥化療的臨床獲益,包括不同的 PD-L1 表達水平或組織學分型。與治療相關的任何等級和 3-4 級不良事件在 NIVO + IPI + chemo 組分別為 92% 和 48% VS 化療組為 88% 和 38%。

Results: At a minimum follow-up of 24.4 months for OS (database lock: Feb 18, 2021), pts treated with NIVO + IPI + chemo continued to derive OS benefit vs chemo, with a median OS of 15.8 months vs 11.0 months, respectively (HR, 0.72 [95% CI, 0.61–0.86]); 2-year OS rates were 38% vs 26%. Median PFS with NIVO + IPI + chemo vs chemo was 6.7 months vs 5.3 months (HR, 0.67 [95% CI, 0.56–0.79]); 8% and 37% of pts who had disease progression received subsequent immunotherapy, respectively. ORR was 38% with NIVO + IPI + chemo vs 25% with chemo. Similar clinical benefit with NIVO + IPI + chemo vs chemo was observed in all randomized pts and across the majority of subgroups, including by PD-L1 expression level (Table) or histology. Any grade and grade 3–4 treatment-related adverse events were reported in 92% and 48% of pts in the NIVO + IPI + chemo arm vs 88% and 38% in the chemo arm, respectively.

Summary of efficacy outcomes by PD-L1 expression.

PD-L1
< 1%

PD-L1
< 1%

PD-L1
≥ 1%

PD-L1
≥ 1%

PD-L1
≥ 50%

PD-L1
≥ 50%

All randomized

All randomized

NIVO + IPI + chemo

n = 135

Chemo


n = 129

NIVO + IPI +chemo

n = 204

Chemo


n = 204

NIVO + IPI +chemo

n = 76

Chemo


n = 98

NIVO + IPI +chemo

n = 361

Chemo


n = 358

Median OS, months

17.7

9.8

15.8

10.9

18.9

12.9

15.8

11.0

OS HR (95% CI)
vs chemo

0.67(0.51–0.88)

-

0.70(0.56–.89)

-

0.67(0.46–.97)

-

0.72(0.61–0.86)

-

2-year OS rate, %

37

22

41

28

45

32

38

26

2-year PFS rate, %

20

5

20

9

28

10

20

8

ORR, n (%)

42 (31)

26 (20)

87 (43)

57 (28)

38 (50)

31 (32)

137 (38)

91 (25)

Median duration of response, months

17.5

4.3

11.8

5.6

26.0

5.4

13.0

5.6

Responders with ongoing response
≥ 2 years, %

45

0

33

13

52

16

34

12

結論:在晚期 Nsclc 的 pts 治療中,至少2年的隨訪、一線 NIVO + IPI + chemo 方案具有持久生存和臨床獲益;未發現新的安全信號。

Conclusion: With 2 years’ minimum follow-up, first-line NIVO + IPI + chemo demonstrated durable survival and benefit versus chemo in pts with advanced NSCLC; no new safety signals were identified.

分享:

相關文章

    評論

    我要跟帖
    發表
    回複 小鴨梨
    發表

    copyright©醫學論壇網 版權所有,未經許可不得複製、轉載或鏡像

    京ICP證120392號 京公網安備110105007198 京ICP備10215607號-1 (京)網藥械信息備字(2022)第00160號
    //站內統計//百度統計//穀歌統計//站長統計
    *我要反饋: 姓 名: 郵 箱: